Screening Triage and Risk Stratification

Launched by UNIVERSITY OF AARHUS · Feb 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how well different tests can help predict the risk of more serious cervical problems in women who have tested positive for HPV (a virus linked to cervical cancer). Specifically, the researchers are looking at various methods, like cytology (cell analysis) and DNA testing, in two groups of women: those aged 50-64 who are part of a cervical cancer screening program and those aged 23-64 who are being monitored after treatment for cervical issues. The goal is to see which tests are the most effective in identifying women who might be at higher risk for conditions like CIN2+ (a type of abnormal cells that can lead to cancer).

To participate in this trial, women must be HPV-screen-positive and fall within the specified age ranges. Those who have had treatment for cervical issues and are undergoing follow-up testing may also be eligible. Participants can expect to undergo a series of tests to monitor their health, and the study will help improve how doctors screen and manage women at risk for cervical cancer in the future. It's important to note that the trial is currently recruiting participants, and anyone interested should check if they meet the criteria.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • HPV-screen-positive (aged 50-64)
• • Women who undergo test-of-cure (i.e. HPV and cytology) six months after LEEP in Central Denmark Region (aged 23-64)
• • Women who undergo follow-up test (i.e. HPV and cytology) 12 months after LEEP
• • A valid cytology-triage result (aged 23-64)
• Exclusion Criteria:
• • Listed in the registry as a person who have rejected to participate in research
• • Invalid cytology and HPV result six months after LEEP
• • No residual material available